The Fibrosis-4 (AST, ALT, PLT, and patient age; FIB-4) and AST to Platelet Ratio Index (APRI), as well as FibroTest (GGT, bilirubin, alpha-2-macroglobulin, haptoglobin, apolipoprotein A-I), have been validated in chronic liver diseases: alcoholic liver disease, NAFLD, chronic hepatitis C, and chronic hepatitis B [51,52]. This evidence concerns the gene A2M and metabolic dysfunction-associated steatotic liver disease.